These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients. Konstantinou MP; Dutriaux C; Gaudy-Marqueste C; Mortier L; Bedane C; Girard C; Thellier S; Jouary T; Grob JJ; Richard MA; Templier C; Sakji L; Guillot B; Paul C; Meyer N Acta Derm Venereol; 2014 Jan; 94(1):45-9. PubMed ID: 23824275 [TBL] [Abstract][Full Text] [Related]
48. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069 [TBL] [Abstract][Full Text] [Related]
49. Multiple colon perforation as a fatal complication during treatment of metastatic melanoma with ipilimumab - case report. Dilling P; Walczak J; Pikiel P; Kruszewski WJ Pol Przegl Chir; 2014 Feb; 86(2):94-6. PubMed ID: 24670341 [TBL] [Abstract][Full Text] [Related]
50. Subclinical aortitis after starting nivolumab in a patient with metastatic melanoma. A case of drug-associated aortitis? Loricera J; Hernández JL; García-Castaño A; Martínez-Rodríguez I; González-Gay MÁ; Blanco R Clin Exp Rheumatol; 2018; 36 Suppl 111(2):171. PubMed ID: 29799390 [No Abstract] [Full Text] [Related]
51. Ipilimumab in patients with melanoma and brain metastases. Nieder C Lancet Oncol; 2012 Jul; 13(7):e277; author reply e277-8. PubMed ID: 22748259 [No Abstract] [Full Text] [Related]
52. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. Kähler KC; Hassel JC; Heinzerling L; Loquai C; Mössner R; Ugurel S; Zimmer L; Gutzmer R; J Dtsch Dermatol Ges; 2016 Jul; 14(7):662-81. PubMed ID: 27373241 [TBL] [Abstract][Full Text] [Related]
53. Left Ventricular Dysfunction After Treatment With Ipilimumab for Metastatic Melanoma. Roth ME; Muluneh B; Jensen BC; Madamanchi C; Lee CB Am J Ther; 2016; 23(6):e1925-e1928. PubMed ID: 26885708 [TBL] [Abstract][Full Text] [Related]
56. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. Jain A; Lipson EJ; Sharfman WH; Brant SR; Lazarev MG World J Gastroenterol; 2017 Mar; 23(11):2023-2028. PubMed ID: 28373768 [TBL] [Abstract][Full Text] [Related]
57. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Weber JS; Amin A; Minor D; Siegel J; Berman D; O'Day SJ Melanoma Res; 2011 Dec; 21(6):530-4. PubMed ID: 22051508 [TBL] [Abstract][Full Text] [Related]
58. Renal Allograft Failure After Ipilimumab Therapy for Metastatic Melanoma: A Case Report and Review of the Literature. Jose A; Yiannoullou P; Bhutani S; Denley H; Morton M; Picton M; Summers A; van Dellen D; Augustine T Transplant Proc; 2016 Nov; 48(9):3137-3141. PubMed ID: 27932166 [TBL] [Abstract][Full Text] [Related]
59. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma. Maurice C; Schneider R; Kiehl TR; Bavi P; Roehrl MH; Mason WP; Hogg D Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960 [TBL] [Abstract][Full Text] [Related]